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Abstract
BACKGROUND: Emergence of additional chromosomal abnormalities (ACAs) in chronic myeloid leukemia (CML) is 
associated with disease progression to advanced phases and reflects the genetic instability of CML.
AIM: Is to evaluate the frequency of ACAs in chronic phase (CP) and advanced disease (AP) CML patients and study 
their impact on patient’s outcome, overall survival (OS) and event-free survival (EFS).
RESULTS: The studied group (n = 73) included 31 males (43%) and 42 females (57%). Median age of patients at 
diagnosis was 37 years (17–76). Median TLC was 208×109/L (2.1–784.2), median Hb was 9.4 g/dL (5.7–13), and 
median platelets count was 290.5×109/L (13–1271). We identified 32 patients (44%) with ACAs. ACAs emergence 
was significantly associated with advanced phases of CML (13/21, 62%) compared to CP (19/52, 36%) (p = 0.048). 
ACAs were associated with lower median OS and EFS in CP compared to AP (38 vs. 120 ms) and (58.3 vs. 77 ms) 
(p = 0.026 and p = 0.065, respectively). Early molecular responders (6/17, 35%) at 3 months, and 6 months 
(10/26, 38%) developed ACAs less than nonoptimal responders. Disease phase, hepatomegaly and bone marrow 
eosinophilia were significant predictors of OS (p < 0.001, p = 0.02, p = 0.04, respectively).
CONCLUSION: Early identification of ACAs in Ph+ metaphases at diagnosis and during therapy predicts CML 
outcome. ACAs emergence occurred at a higher frequency and at a younger age in our CML patients and are related 
to inferior EFS and OS.
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Introduction
Chronic myeloid leukemia (CML) is a clonal 
myeloproliferative neoplasm characterized by the 
presence of the Philadelphia (Ph) chromosome, 
produced by the reciprocal translocation t(9;22)
(q34;q11) [1]. This translocation leads to the generation 
of the chimeric fusion gene BCR-ABL1 [2]. At diagnosis, 
additional chromosomal abnormalities (ACAs) in Ph+ 
cells may appear in ~ 5% of patients. The proportion of 
patients with ACAs rises during the course of the disease 
to ~ 80% in the blast phase (BP), according to several 
series [3], [4]. Despite the efficacy of imatinib mesylate 
(IM) in CML – chronic phase (CP), treatment failure, or 
suboptimal response have been reported [5], [6]. The 
appearance of ACAs during tyrosine kinase inhibitor 
(TKI) treatment is commonly known as clonal evolution 
(CE) and seems to play an important role in IM 
resistance and is considered to be a poor prognostic 
feature [7]. The World Health Organization (WHO) 
suggests that CML patients showing ACAs emerging 
during treatment should be considered in accelerated 
phase (AP) [8] and European Leukemia Network 
(ELN) recommendations suggest that the presence of 
ACAs at diagnosis may represent a “warning” feature, 
requiring careful monitoring of the patient. Emerging 
ACAs during the course of treatment represent the 
failure of treatment [9], [10]. The aim of the current 
study is to investigate the frequency and prognostic 
impact of ACAs in a cohort of Egyptian CML patients, 
either at diagnosis or during the disease course, and to 
study their impact on response to TKI therapy and CML 
patient’s survival.
Patients and Methods
Patients
This study was conducted on 73 CML Egyptian 
patients either newly diagnosed or under TKI treatment 
who presented to the outpatient clinic of Medical 
Oncology Department of National Cancer Institute from 
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January 2015 to January 2017. Median follow-up time 
was 24 ms (1–121 ms). Informed consent was provided 
by all included subjects and the study was approved 
by the Institutional Review Board. Eligible patients 
were >18 years fulfilling morphologic and cytogenetic 
criteria of Ph+ CML in (CP), (AP), or (BP) according 
to definitions in the revised 4th edition of the WHO 
classification [8].
Treatment
The included CML patients who were 
previously treated with a TKI received one or more of 
either a first-generation TKI (IM, IM/ GLIVEC®, 400 mg 
orally once per day or generic imatinib) or a second-
generation TKI (Nilotinib/TASIGNA® or Dasatinib/
SPRYCYL®). Hydroxycarbamide (1–6 g/day orally) 
was given to CML-CP patients as initial cytoreductive 
therapy until BCR-ABL1 results by fluorescence in situ 
hybridization (FISH) were available.
Definition of responses to TKI treatment
Hematologic, molecular, and cytogenetic 
remissions were defined according to the National 
Comprehensive Cancer Network guidelines [11]. 
Definitions of molecular response were defined 
according to ELN recommendations [12].
Measurements of survival
Event free survival (EFS) was defined as loss 
of hematologic or cytogenetic response or development 
of advanced phases of CML (AP or BP) and overall 
survival (OS) by absence of death from any reason [13].
Methodology
Cultivated bone marrow (BM) samples of all 
included patients were subjected to chromosomal 
banding analysis to detect the presence of ACAs in Ph+ 
cells. ACAs were classified as major route abnormalities 
that included: +8, a second Philadelphia chromosome 
(der 22), +19, i(17q10) [4], and minor route abnormalities 
that included: +21, −7, −17, del (Y) and 3q26.2, and 
other abnormalities [9]. The detected chromosomal 
abnormalities were confirmed using FISH molecular 
probes provided by Cytocell (UK) and MetaSystems 
(Germany). Diagnostic and serial measurements of 
BCR-ABL1 fusion gene mRNA transcript level were 
done by real-time quantitative polymerase chain 
reaction according to IS on GeneXpert, Cepheid.
Conventional cytogenetics study
At least 20 metaphases were analyzed for 
each sample after trypsinization and staining slides 
with Giemsa. Metaphase capture and image analysis 
were performed using Metafer 4/MetaClient software 
analysis program (MetaSystems) and CytoVision 
(Applied Imaging). Chromosomal abnormalities were 
described according to the International System for 
Human Cytogenetics Nomenclature (ISCN, 2016) [14].
FISH
The following FISH probes were used: 
BCR/ABL translocation (Dual Fusion Probe), 17p 
subtelomere specific probe, 17q subtelomere 
specific probe, Del (20q) deletion probe and EVI1 
(MECOM) break apart probe (Provided by Cytocell 
Aquarius) and XCP (XCyting Chromosome Paints) 
for chromosome 8, chromosome 19, chromosome 7, 
chromosome 21, and Del (7q) (q22q31) (MetaSystems 
Probes GmbH 1.Industriestr.7).
Statistical methodology
Statistical analysis was done using IBM 
SPSS® Statistics version 22 (IBM® Corp., Armonk, NY, 
USA). Numerical data were expressed as mean and 
standard deviation or median and range as appropriate. 
Qualitative data were expressed as frequency and 
percentage. Pearson’s Chi-square or Fisher’s exact 
tests were used to examine the relationship between 
qualitative variables. For not normally distributed 
quantitative data, a comparison between the two 
groups was done using the Mann–Whitney test (non-
parametric t-test). Survival analysis was done using 
the Kaplan–Meier method and a comparison between 
two survival curves was done using the log-rank 
test. Multivariate analysis was done using the Cox-
regression method for the factors affecting survival 
on univariate analysis. Hazard ratio (HR) with its 95% 
confidence interval (CI) was used for risk estimation. 
All tests were two-tailed. A p < 0.05 was considered 
statistically significant.
Results
Seventy-three CML patients were included, 
31 (43%) males and 42 (57%) females. Fifty-two/73 
(71%) patients were in CP, 6(8%) patients were in AP, 
and 15(20%) patients were in BP. Patients with AP 
and BP were grouped together as advanced phase 
disease (21, 29%). The median age of CP patients at 
diagnosis was 39 years (17–76) and 35 years (22–54) 
for AP. Median TLC was 225×109/L (2.1–784.2) for CP 
patients and 127×109/L (13.5–353) for AP, median Hb 
was 10 g/dL (5.7–13) for CP and 8.8 g/dL (7.1–11.5) 
for AP, and median platelets count was 319×109/L 
(123–1173) for CP and 237.5×109/L (13–1271) for 
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AP. Median PB blast % was 2% (0–9) for CP and 
6% (0–92) for AP, median PB eosinophils was 3% 
(0–8) for CP and 2% (0–13) for AP, and median PB 
basophils was 3% (0–12) for CP and 3% (0–23) for 
AP. Median BM blast % was 2% (0–8) for CP and 
25% (10–91) for AP, median BM basophils was 4% 
(0–11) for CP and 5% (0–17) for AP, and median BM 
eosinophils was 5% (0–14) for CP and 4% (0-16) for 
AP. Time to TKI treatment ranged from 6 to 150 days, 
with a median of 33 days. Sixty-eight patients (93%) 
were treated with 1st line TKI upfront (Gleevec® or 
generic IM) and 5 patients (7%) received a 2nd line TKI 
as upfront therapy (Nilotinib/Tasigna® or Dasatinib/
Sprycel®). Forty three/52 (83%) were tolerant to TKI 
therapy, while 9 patients (17%) were intolerant. Ten/52 
(19%) CP and 17/21 (81%) AP patients died by the 
end of study duration. Cumulative OS of CP patients 
at 12 months was 90% and at 24 months was 84% 
and was 71% and 42% for AP patients at 12 months 
and 24 months, respectively (p < 0.001). EFS of CP 
patients (38/52) was 73% by the end of 24 months 
follow-up duration.
Evaluation for emergence of ACAs
Thirty two/73 (44%) patients developed ACAs; 
22 at diagnosis (16 CP and 6 AP patients) and 10 patients 
later during the course of the disease (3 CP and 7 AP 
patients). The reported 32 ACAs were 18 (56%) major 
route abnormalities, 4 (12%) minor route abnormalities, 
and 5 (16%) patients with more than one ACAs (major 
and minor) and 5 patients (16%) were found to express 
other (non-major/non-minor) secondary chromosomal 
changes. Ten/18 (56%) patients developed major route 
abnormalities at diagnosis and 8/18 (44%) patients 
during the course of disease, while 2/5 (40%) patients 
developed both major and minor route abnormalities 
during the course of disease and 3/5 (60%) at diagnosis. 
Minor route abnormalities were detected in 4 patients 
at diagnosis, while other chromosomal abnormalities 
were detected in 5 patients at diagnosis. Four/5 AP 
patients were identified with hyperdiploid karyotype and 
developed acute lymphoblastic leukemia BP and one 
patient developed mixed phenotype acute leukemia 
during disease course Table 1 describes ACAs in 32 CML 
patients.
Table 1: ACAs emergence in 32/73 CML patients
UPN Age Gender Phase Time of emergence Karyotype Major/Minor/others TKI upfront
3 22 F ABC During course 51,XX,+8,+9,+10, +19,+22,der(22), t(9;22)(q34;q11)
[16]/47,2q+,t(9;22)(q34;q11)[4]
Major 1st line
6 34 M ABC During course 52,XY,+8,+10,+11,11q-,+14,+21,+22, der(22), t(9;22)(q34;q11) 
[10]/46, XY, t(9;22)(q34;q11) [10]
Major 1st line
8 54 F ABC At diagnosis 45,XX,−7 , t(9;22)(q34;q11)[4]/46, XX, t(9;22) (q34;q11) [16] Minor 1st line
9 26 F CP At diagnosis 46,XX, t(9;22)(q34;q11)[10]/44, XX, −10,-15, −20, +22, t(9;22)
(q34;q11)[10]
Minor 1st line
10 58 F CP During course 48,XX,+19,+22,der(22), t(9;22)(q34;q11)[4]/47,XX,der(22), 
t(9;22)(q34;q11)[6]/46,XX t(9;22)(q34;q11)[10]
Major 1st line
11 38 F CP At diagnosis 48,XX, +8,+22,der(22), t(9;22)(q34;q11) [8]/47,XX,+19,t(9;22)
(q34;q11) [6]/46,XX, t(9;22)(q34;q11) [6]
Major 1st line
13 33 F CP At diagnosis 46, XX, t(9;22) (q34;q11)[3]/46,XX, −7, +17 [7]/45, XX, −7 [10] Minor 1st line
16 27 F CP At diagnosis 47,XX, −2,+8,+19, t(9;22)(q34;q22) [4]/46,XX,  
t( 9;22)(q34;q22) [16]
Major 1st line
18 26 M CP At diagnosis 44, X, del (y), −17, t (9;22)(q34;q11) [8]/46, XY,  
t(9;22)(q34;q11) [12]
Minor 1st line
19 32 F ABC At diagnosis 47, XX, +22, der (22), t(9;22)(q34;q11) [18]/ 46, XX [2] Major 1st line
20 23 F CP At diagnosis 47, XX, +22, der(22), t(9;22)(q34;q11) [3]/46, XX, t(9;22)
(q34;q11) [17]
Major 1st line
27 40 M AP During course 47,XY, +8,11q-, t(9;22)(q34;q11) [15]/ 46,XY, t(9;22)(q34;q11) [5] Major 1st line
39 26 M ABC During course 47, XY, +8, del (6q) ,t(9;22)(q34;q11) [15]/ 46, XY, t(9;22)
(q34;q11) [5]
Major 1st line
40 31 M CP At diagnosis 45, XY, −9,t(9;22)(q34;q11) [14]/46, XY, t(9;22)(q34;q11) [6] Other 1st line
41 35 F ABC At diagnosis 47, XX, +21, t(8;21)(q22;q22), t(9;22)(q34;q11) [15]/46, XX, 
t(9;22)(q34;q11) [5]
Other 1st line
42 18 M CP At diagnosis 47, XY, +8, t(9;22)(q34;q11) [16]/46, XY, t(9;22)(q34;q11) [4] Major 1st line
43 26 F CP At diagnosis 46,XX, der(1q), t(9;22)(q34;q11) [20] Other 1st line
45 23 M CP At diagnosis 48, XY,+8, der (22), t(9;22)(q34;q11)[18]/46,  
XY, t(9;22)(q34;q11)[2]
Major 1st line
46 48 M CP During course 47, XY, +4, t(9;22)(q34;q11)[6]/47,XY,+8, t(9;22)(q34;q11)[8]/47, 
XY,der (22),t(9;22)(q34;q11)[18]
Major 1st line
50 56 F CP At diagnosis 47,XX,+22, der (22), t(9;22)(q34;q11) [6]/47,XX,+19,t(9;22)
(q34;q11) [4]/46,XX, t(9;22)(q34;q11) [10]
Major 1st line
51 29 M ABC During course 48, XY, +8, +22, der (22), t (9;22)(q34;q11) [16]/ 46,XY , t(9;22)
(q34;q11) [4]
Major 2nd line
53 17 M CP During course 46, X , del (Y), +8, t(9;22)(q34;q11) [20] Major and minor 1st line
54 18 M CP At diagnosis 46,XY, t(9;22)(q34;q11) [10]/59,XY, der(22), t(9;22)(q34;q11) [10] Major 1st line
55 27 F ABC At diagnosis 46, XX, −7, +19, t(9;22)(q34;q11) [8]/47, XX, −7, +19, +22, der 
(22), t(9;22)(q34;q11) [4]/46,XX [8]
Major and minor 2nd line
60 42 M ABC During course 46, XY, −7,+22, der(22), t(9;22)(q34;q11) [12]/45,XY, −7, t(9;22)
(q34;q11) [8]
Major and minor 1st line
62 44 F AP At diagnosis 46, XX, +4, −7, −17, der (22) , t(9;22)(q34;q11) [15]/46, XX, 
t(9;22)(q34;q11) [5]
Major and Minor 1st line
64 50 F CP At diagnosis 46,XX, , t (9;11;22)(q34;q23;q11) [20] , Variant Ph ch. Other 1st line
65 54 M CP At diagnosis 45, XY, +13, −17, −20[5]/46, XY, t(9;22)(q34;q11)[15] Major and minor 1st line
66 55 M CP At diagnosis 53, XY, +4, +8,+10,+12, +15, +19, +22, der(22), t(9;22)(q34;q11)
[18]/48, XY,+4, +22, der(22), t(9;22)(q34;q11)[2]
Major 1st line
67 23 F ABC At diagnosis 47,XX, t(1;3),t(14;21), t(16;21), +22, der(22), t(9;22)(q34;q11) 
[20](complex karyotype)
Major 1st line
69 27 M AP During course 50, XY,+4,+8,+10,+22,der(22), t(9;22)(q34;q11) [18]/46,XY, 
t(9;22) (q34;q11) [2]
Major 1st line
72 31 F CP At diagnosis 46,XX, der(1q), t(9;22)(q34;q11) [20] Other 1st line
ACAs: Additional chromosomal abnormalities, CML: Chronic myeloid leukemia, CP: Chronic phase.
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Emergence of ACAs and CML patient’s 
characteristics
AP patients developed ACAs at a higher 
percentage (13/21, 62%) compared to CP patients 
(19/52, 36%) (p = 0.048). Patients <40 years had a 
higher incidence of developing ACAs than patients ≥40 
years (p = 0.034). A higher percentage of patients with 
normo/hypocellular BM smears (7/8, 87%) developed 
ACAs compared to (25/65, 38%) with hypercellular 
BM at diagnosis (p = 0.018). A higher percentage of 
patients with splenomegaly at diagnosis (31/64, 48%) 
developed ACAs compared to (1/9, 11%) patients with 
no splenomegaly (p = 0.035).
ACAs and TKI response
CML patients who failed to achieve EMR had 
more ACAs (6/13, 46%) compared to (6/17, 35%) patients 
who achieved EMR (p = 0.547). A higher percentage 
of CML-CP patients (n = 52) who achieved an optimal 
molecular response were free of ACAs at diagnosis 
(13/18, 72%) compared to CP patients with ACAs at 
diagnosis (5/18, 28%) (p = 0.063). We also noted that 
CML-CP patients who were free of ACAs at diagnosis were 
tolerant to their received TKIs (20/34, 83%) compared to 
patients with ACAs (14/34, 41%) (p = 0.316).
OS and EFS in relation to ACAs
CML patients free from ACAs (41/73, 56%) 
had a significantly higher median OS (120 vs. 38 
months) than those who developed ACAs (32/73, 
44%) at diagnosis or during disease course (p = 0.026) 
(Figure 1).
Figure 1: Additional chromosomal abnormalities and overall survival 
(p = 0.026)
Patients with no ACAs (41/73, 56%) had 
a higher median OS than patients with major route 
abnormalities (23/73, 31%) (120 vs. 40 months) in 
Figure 2: Overall survival by additional chromosomal abnormalities 
category (p = 0.084)
pairwise comparison analysis (p = 0.084) (Figure 2). 
CML-CP patients (n = 52) who were free of major 
route ACAs by end of follow-up time (33/52, 63%) had 
a superior cumulative EFS at 24 months than patients 
who developed major route abnormalities (12/52, 23%) 
(77% vs. 58.3%) (p = 0.065) (Figure 3).
Figure 3: Relationship between additional chromosomal abnormalities 
category and event-free survival (p = 0.065)
Correlations between TKI response and 
patients survival
The patterns of molecular response and its 
relation to OS and EFS in 52 CML-CP patients are 
described in Table 2. We also report that CML-CP 
patients (n = 52) who shifted to generic IM had a higher 
cumulative OS (85% vs. 66%) and EFS (88% vs. 66%) 
at 24 months than patients who had frequent treatment 
interruptions due to unavailability of Glivec® (p = 0.087 
and p = 0.100, respectively).
Correlations between patients 
characteristics and OS and EFS
Female patients had a higher median OS 
than males (p = 0.033). CML-CP patients had a higher 
cumulative survival at 24 months (84%) than patients 
presenting with CML-AP (42%) (p < 0.001) (Figure 4).
Patients presenting with thrombocytopenia 
had a lower median OS (20 months) than patients 
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Figure 4: Overall survival according to chronic myeloid leukemia 
phases at presentation (p < 0.001)
who presented with higher platelet counts (40 months) 
(p = 0.070). Patients with normo/hypocellular BM 
had a lower median OS than patients presenting with 
hypercellular BM (36 vs. 69 months) (p = 0.074). 
Patients with BM eosinophilia (≥5%) had a higher 
median OS than patients with BM eosinophils count 
<5% (36 vs. 69 months) (p = 0.01). OS was higher 
in patients with splenomegaly (73%) (p = 0.978) and 
hepatomegaly (85%) (p = 0.079) compared to their 
normal counterparts (67% and 60%, respectively). 
Table 3 illustrates the subgroups of variables considered 
for the OS comparison between CP and AP groups of 
CML patients.
Predictors of survival in Egyptian CML 
patients
Multivariate analysis of CML patients categorical 
variables included factors affecting OS in univariate 
analysis (gender, thrombocytopenia [platelets count 
<100×109/L]), BM cellularity, BM eosinophilia (≥5%), 
disease stage (CP vs. AP), presence of ACAs, and 
presence of hepatomegaly). Factors that were predictors 
of OS were the phase of CML disease, BM eosinophilia, 
and hepatomegaly. AP patients (n = 21) were 7 times more 
liable to death than CP patients (n = 52) (HR = 6.97 95%, 
CI: 3.03–15.96, p < 0.001), patients with no hepatomegaly 
(39/73) were 2.8 times more liable to death than patients 
with hepatomegaly (33/73) (HR = 2.8, 95% CI: 1.20–-
6.52, p = 0.017), and a finding that denotes presence of 
hepatomegaly was protective in the studied CML group and 
patients with no BM eosinophilia (≥5%) were 2.37 times 
more liable to death than patients with BM eosinophilia 
(HR = 2.37, 95% CI: 1.053–5.376, p = 0.037).
Discussion
Mechanisms of resistance to TKIs in CML 
include genomic amplifications, point mutations of the 
Table 2: Patterns of molecular responses and OS and EFS in 52 CML-CP patients
Type of molecular response Frequency (%) Major route ACAs 
(n=10/52) (%)
ACAs (n=19/52) 
n.(%)
Cum OS at 
24 ms (%)
p Cum EFS at 
24 ms (%)
p
EMR (3 months) BCR-ABL1 ratio: (n=52)
<10% (optimal response) 30 (58%) 3 (30%) 10 (33%) 76 0.656 90 0.051
≥10% 22 (42%) 7 (78%) 9 (41%) 77 61
6 months BCR-ABL1 ratio: (n=52)
<1% (optimal response) 36 (68%) 6 (46%) 13 (36%) 92.3 0.204 89 0.049
≥ 1% 16 (31%) 4 (57%) 7 (44%) 83.3 70
MMR (12 months) BCR-ABL1 ratio: (n=52)
<0.1% (optimal response) 25 (48%) 3 (37%) 8 (32%) 95 0.276 89 0.241
≥ 0.1% 27 (52%) 7 (64%) 11 (41%) 90.5 65
DMR (18 months) BCR/ABL1 ratio: (n=52)
<0.01% (optimal response) 20 (38%) 4 (67%) 6 (30%) NR 0.424 89 0.244
≥0.01% 32 (61%) 6 (46%) 13 (40%) NR 60
At 24 months (n=52):
<0.0001% (undetectable BCR-ABL1 ratio) (optimal response) 12 (23%) 4 (100%) 4 (33%) NR NR 67 NR
≥0.0001% 40 (80%) 6 (40%) 15 (37%) NR 83
Type of response to TKI therapy:
Optimal 18 (35%) 3 (60%) 5 (28%) 94.4 0.125 94 0.065
Suboptimal (warning ) 10 (19%) 2 (50%) 4 (40%) NR 79
Failure 24 (46%) 5 (50%) 10 (42%) 70.8 57
EMR: Early molecular response, MMR: Major molecular response, DMR: deep molecular response, NR: Not reached, CML-CP: Chronic myeloid leukemia-chronic phase, ACAs: Additional chromosomal abnormalities,  
OS: Overall survival, EFS: Event-free survival, TKI: Tyrosine kinase inhibitors.
Table 3: Predictors of OS in CML-CP and AP phases of CML
Parameter n (%) No of deaths (%) Cum survival at 12 months (%) Cum. survival at 24 months (%) Median survival (months) p
Totals CP AP CP AP CP AP CP AP CP AP
52 21 10 (19%) 17 (81%) 90 71 84 42 * 20
Age (years)
<40 26 (50) 14 (67) 3 (11) 11(79) 92 71 88 36 * 18 <0.001
≥40 26 (50) 7 (33) 7 (27) 6 (86) 89 71 80 57 * 36 0.066
Gender
Male 22 (42) 9 (43) 7 (32) 9 (100) 86 78 71 22.2 40 17 0.004
Female 30 (58) 12 (57) 3 (10) 8 (67) 93 67 * 57.1 * 36 <0.001
ACAs
Present 19 (36) 13 (62) 6 (32) 10 (77) 84 77 73 45 40 20 0.075
Absent 33 (63) 8 (38) 4 (12) 7 (87) 94 63 91 37 * 13 <0.001
ACAs category
None 33 (63) 8 (38) 4 (12) 7 (87) 94 63 91 37 * 13 <0.001
Major + (major and 
minor).
12 (23) 11 (52) 4 (33) 8 (73) 83 81 75 44 40 20 0.172
Minor + others 7(14) 2 (10) 2 (29) 2 (29) 86 50 71 * * 8 ------
Hepatomegaly
No 28 (54) 11 (52) 7 (25) 10 (91) 86 45 78 18 * 12 <0.001
Yes 24 (46) 10 (48) 3 (13) 7 (70) 96 * 92 69 * 38 0.019
ACAs: Additional chromosomal abnormalities, CML-CP: Chronic myeloid leukemia-chronic phase, AP: Advanced phase, CP: Chronic phase. P value < 0.05 is considered significant.
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ABL tyrosine kinase domain, and emergence of 
ACAs [15]. The median age of patients at diagnosis was 
37 years which is comparable to previous studies in 
Pakistan, Nigeria, Mexico [16], [17], [18], and previous 
Egyptian reports [19], [20]. In our study, we found that 
patients <40 years tended to develop ACAs more than 
patients ≥40 years (55% vs. 30%), respectively 
(p = 0.034). Similarly, median age (27 years) of patients 
who developed trisomy 8, a major route abnormality 
was higher than the median age of patients (40 years) 
who were free from the same abnormality (p = 0.023). 
The same observation was detected when comparing 
the median age of CML patients with an extra 
Philadelphia chromosome (17/73, 32 years) and without 
the same abnormality (56/73) (38 years) (p = 0.225). 
These findings matched those of GIMEMA working 
group who reported a lower median age of 45 years in 
patients with ACAs compared to 50 years in patients 
without ACAs [21]. Our findings also matched those 
reported by the German CML study Group IV who 
reported a lower median age of 48 years in patients with 
ACAs compared to 53 years in patients with the sole 
standard t (9;22) abnormality [22]. In our study, the 
incidence of ACAs was 44% (32/73) and this was higher 
than the highest previously reported incidence by others 
(15%, 6%, 7%, and 24%), respectively [16], [21], [22], [23]. 
In addition, the incidence of major route abnormalities 
was 18/73, 25%. Our observed incidence was 
comparable to two other reports showing an ACAs 
incidence of 42% and 30%, respectively [24], [25]. 
Incidence of emergence of ACAs in our CML-CP patients 
was 36% and 62% in AP (p = 0.048). These findings 
were in agreement with previously reported data by 
others [23], [26]. We found that a significantly higher 
percentage of patients with splenomegaly (48%) 
developed ACAs during their disease course compared 
to 11% of patients with no splenomegaly (p = 0.035). 
This finding was in accordance with a previous 
study [21], who reported a higher median increased 
spleen size (4 cm) in patients with ACAs compared to a 
median of 2 cm in those without ACAs. This finding 
could be explained by the fact that CML patients with a 
higher Sokal prognostic score at diagnosis have a higher 
probability to develop ACAs [13]. We also describe an 
association between hepatomegaly at presentation and 
a higher median OS (p = 0.086) in univariate survival 
analysis as the presence of hepatomegaly was found to 
be protective and a favorable independent predictor of 
OS in the multivariate model (HR = 2.80, 95% CI: 1.20–
6.52, p = 0.017). The protective role of hepatomegaly 
could be explained by the fact that liver represents an 
extramedullary site of hematopoiesis that takes over this 
process in the event of BM infiltration by myeloid 
elements as observed in CML, thus maintaining other 
blood lineages physiological counts and providing tumor 
infiltrating lymphocytes to carry on an effective anti-
tumor immune response. In this work, CML patients with 
hypercellular BM smears at presentation developed less 
ACAs than those who presented with a normal or 
reduced BM cellularity (p = 0.018), explained in light of 
the presence of concomitant BM fibrosis in patients with 
reduced BM cellularity at the presentation which would 
classify these patients as an advanced disease (AP) 
CML even before any evidence of CE, an explanation 
confirmed by BM trephine specimens examination of 
included CML patients [8]. BM basophils <3% in our 
CML-CP patients (n = 52) was significantly associated 
with a higher median EFS than patients with BM 
basophils ≥3% (p = 0.049). This finding was in agreement 
with that reported by Cortes et al., 2003 [23], who used 
a 5% cutoff for BM basophils and observed the same 
relationship between the two groups of CP patients and 
achieving MCyR. However, we found a different 
relationship between BM eosinophilia (≥5%) and OS in 
our Egyptian CML patients describing eosinophilia to be 
a favorable prognostic factor and independent predictor 
of survival in Egyptian CML patients upon univariate 
(p=0.014) and multivariate analyses models (p = 0.037, 
HR = 2.38, 95% CI = 1.05-5.38). This was different to 
what was reported by the Hasford and EUTOS scoring 
systems to evaluate risk groups in CML patients [27]. 
The mentioned scoring systems utilize PB eosinophils 
percentage in its formula, denoting that a higher PB 
eosinophils % results in a higher patient score and 
higher risk category. Although PB eosinophils percentage 
and not BM eosinophils are included in Hasford and 
EUTOS scoring systems [27], the current finding in this 
study introduces BM eosinophils percentage as an 
independent predictor of OS in Egyptian CML patients 
and a variable that could be potentially introduced in risk 
stratification of CML in middle-Eastern populations, 
although larger cohort studies are needed to justify this 
attempt. Patients with thrombocytopenia (<100×109/L) 
had a lower median OS than patients who presented 
with higher platelet counts (p = 0.07) and was found to 
be an independent poor prognostic factor in Egyptian 
CML patients upon the log-rank statistical test of the 
impact of variables on OS (p=0.082). This correlation 
was similar to a previously reported significant correlation 
between thrombocytopenia at presentation and 
unresponsiveness to TKI therapy and lack of MCyR 
which was consequently and significantly correlated 
with OS and EFS [28]. A higher percentage of CML-CP 
patients who failed to achieve optimal response to TKI 
therapy had ACAs (42%) compared to (28%) of optimal 
responders. These findings were comparable to reported 
findings by Cortes et al., 2003, who concluded that 
either CP or AP CML patients who developed ACAs had 
inferior hematologic and cytogenetic responses to TKI 
than their ACAs free counterparts. Our presented 
findings also matched those of the GIMEMA working 
party who reported a lower percentage of optimal 
responders (major molecular response at 12 months) 
among patients with ACAs (67%) compared to 86% 
among patients without ACAs. In the current work, 
median OS of CP patients at the end of 24 months 
follow-up duration could not be reached as more than 
half of patients were still alive and median survival was 
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21 months for AP patients. As expected, the presenting 
phase of CML at diagnosis was found to be an 
independent poor prognostic factor in univariate and 
multivariate analyses with CML-CP patients having a 
significantly higher cumulative OS at 24 months than 
patients with AP (p < 0.001) (HR = 7,95% CI = 3.03–
15.9, p < 0.001).We also found that CML patients who 
were free of ACAs had a significantly higher OS than 
patients who developed ACAs (p = 0.026) and a higher 
cumulative EFS at 24 months (p = 0.065). This finding 
was in accordance with that reported by others [21], [23]. 
We were able to identify a negative impact of major 
route ACAs in a total of 18 patients (11 in CP and 8 in AP 
of CML) on OS and EFS compared to patients with the 
minor route or other abnormalities (p = 0.084 and 
p = 0.065), respectively. We also attempted to evaluate 
the relationship between the type of TKI received upfront 
whether 1st line (IM) or 2nd line (Nilotinib and Dasatinib), 
time to TKI treatment and shift to generic IM and the 
frequency of developing ACAs, molecular response, 
patient’s tolerance to TKIs, and their OS and EFS. We 
found that among patients who developed ACAs 
(n = 32), a larger number of patients had a > 15 days’ 
time to TKI (25/30, 83%) compared to (5/30, 17%) with 
shorter time to TKI (≤15 days) (p = 0.130). This finding 
necessitates earlier therapy from time of diagnosis to 
eliminate CE. We also found that a larger number of 
patients who received 1st line TKI upfront tended to 
develop ACAs (30/32, 94%) compared to those who 
received 2nd line TKI as an upfront therapy (2/32, 6%), a 
finding proving a deeper molecular response achieved 
by 2nd line TKI, affecting survival and elimination of CE. 
In addition, a larger number of patients who had 
interruptions to Glivec® therapy without shifting to other 
generic IM (23/32, 72%) developed ACAs compared to 
those who shifted to a different generic IM without 
treatment interruption (9/32, 28%). We also report that 
CP patients who were tolerant to their received TKIs 
tended to develop ACAs less (14/34, 17%) than their 
counterparts who were defined as intolerant to TKIs 
(2/6, 33%). These observations could be matched with 
previous studies [10], [28], [29]. An interesting 
observation that we report in this study is the near 
significance higher median OS and EFS of CML-CP 
patients who had a shift to a different generic IM during 
their treatment course due to the unavailability of Glivec® 
(p = 0.087 and p = 0.100, respectively). However, due to 
the small number of patients in the crossover to generic 
IM group (n = 22) compared to their counterparts who 
did not receive the same generic drug (n = 43), we could 
not reach a statistically significant difference.
Conclusion
We report a higher incidence of ACAs in our 
Egyptian CML patients at diagnosis and during the course 
of therapy than western populations. The appearance of 
ACAs, particularly, major route abnormalities at diagnosis 
or their emergence during treatment plays an important 
role in defining response to TKI therapy and have a 
negative impact on CML patients response to TKI therapy 
in terms of cytogenetic and molecular responses as a 
major mechanism of resistance to TKI therapy; this finding 
also applies to CML patients presenting in AP of the 
disease. CML patients who developed ACAs, particularly 
major route abnormalities, had a lower OS and EFS 
than their counterparts without ACAs, which proves the 
negative impact of CE in this disease. We conclude that 
the impact of ACAs on response to TKIs therapy in CML 
patients has important clinical and biological implications. 
Our study suggests that the detection of ACAs, besides 
BCR-ABL1 kinase domain mutation, is an important 
determinant of CML patients prognosis and survival. 
Earlier identification of these abnormalities may help in 
adopting more appropriate therapeutic approach.
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